Business Context and Reporting Period
PACS Group, Inc. (PACS) is a leading post-acute healthcare company operating 314 skilled nursing and assisted living facilities across 17 states. This Form 10-K covers the fiscal year ended December 31, 2024. The filing includes a restatement of previously issued financial statements for the quarters ended March 31, 2024, and June 30, 2024, following an Audit Committee investigation into allegations of revenue recognition errors and compliance issues. The company operates under a decentralized model, transforming acquired underperforming facilities into higher-acuity transitional care centers.
Key Financial Metrics (Year Ended December 31, 2024)
- Revenue: $4.09 billion (up 31.4% from 2023), driven primarily by skilled nursing services revenue of $4.09 billion.
- Net Income: $55.3 million (down 51.0% from $112.9 million in 2023).
- Adjusted EBITDA: $279.5 million (up 17.7% from $237.5 million in 2023).
- Operating Expenses: $3.97 billion, with Cost of Services at $3.30 billion and Rent at $285.0 million.
- Cash Flow: Net cash provided by operating activities was $367.3 million. Net cash used in investing activities was $442.7 million, primarily for facility acquisitions ($283.3 million) and capital expenditures ($66.5 million).
- Liquidity: Cash and cash equivalents totaled $157.7 million as of December 31, 2024. The company is currently in a state of forbearance with its lenders and cannot borrow additional amounts under its credit facility.
- Debt: Total long-term liabilities were $3.5 billion. Outstanding debt under the Amended and Restated 2023 Credit Facility was $142.0 million, and HUD-insured mortgage loans totaled $252.9 million.
Material Changes and Restatement
The company restated its financial statements for the first and second quarters of 2024 due to material weaknesses in internal controls. The restatement primarily involved the derecognition of revenue associated with respiratory and certain other therapy services billed under Medicare Part B, which management determined should not have been recognized under ASC 606 due to regulatory uncertainties. Additionally, certain leases were reclassified from operating to finance leases. These adjustments reduced previously reported revenue and net income for the impacted periods. The restatement also triggered a clawback of erroneously awarded executive compensation tied to Adjusted EBITDA performance metrics.
Outlook, Risks, and Contingencies
- Internal Controls: Management identified material weaknesses in the control environment and revenue recognition processes. Remediation efforts include hiring an Interim Chief Compliance Officer, enhancing the compliance hotline, and implementing new revenue review procedures. Disclosure controls and procedures were deemed ineffective as of December 31, 2024.
- Legal and Regulatory: The company is subject to multiple ongoing investigations by the U.S. Department of Justice (DOJ) and the SEC regarding potential violations of the False Claims Act, HIPAA, and financial reporting. These include inquiries into Medicare Part B billing, patient referral inducements, and the use of COVID-era waivers. The company is also facing securities class action and derivative litigation following a short-seller report in November 2024.
- Liquidity and Debt: PACS is in a forbearance agreement with its lenders regarding technical events of default. The company is prohibited from borrowing new loans under its credit facility until the forbearance period ends and an amendment is reached. Management expects to reach an agreement by the end of the forbearance period (extended to November 30, 2025).
- Executive Changes: Former CFO Derick Apt resigned in September 2025 following an investigation into policy violations. Mark Hancock serves as Interim CFO. The company has recouped erroneously awarded bonuses from most executives, though amounts remain outstanding from the founders.
- Guidance: The filing does not provide specific forward-looking financial guidance for 2025 due to the ongoing investigations and restatement. Management focuses on operational improvements, compliance remediation, and executing its acquisition strategy.
Key Facts for Investor Verification
- Verify the status of the forbearance agreement with lenders and the timeline for resolving technical defaults to ensure access to liquidity.
- Monitor the outcomes of the DOJ and SEC investigations, as adverse findings could result in significant fines, penalties, or exclusion from Medicare/Medicaid programs.
- Assess the effectiveness of the remediation plan for material weaknesses in internal controls over financial reporting.
- Review the impact of the restatement on future revenue recognition policies, particularly regarding Medicare Part B ancillary services.
- Track the progress of executive compensation clawbacks and the stability of the leadership team following the resignation of the CFO.